Meat Protein delivers healthy Adjusted EBITDA
Margin of 11.6%, despite transitory headwinds
TSX: MFI
www.mapleleaffoods.com
MISSISSAUGA, ON, August 5,
2021 /PRNewswire/ - Maple Leaf Foods Inc. ("Maple Leaf Foods" or
the "Company") (TSX: MFI) today reported its financial results for
the second quarter ended June 30, 2021.
"As we anticipated, our second quarter faced material market
headwinds and a difficult year-over-year comparable quarter due to
COVID-19 effects, and yet our business delivered excellent results"
said Michael H. McCain, President
and CEO. "In Meat Protein, performance was impressive with sales
growth of 7.4% and Adjusted EBITDA margins of 11.6%. We expect our
margins to fully recover beginning in the third quarter. In Plant
Protein, where we continue to invest for long-term growth, we
expected our sales in the first and second quarters to come in
soft. At the same time, we expect to return to our strategic growth
targets or above in the second half of this year. Our brand
momentum, innovation pipeline and customer activity all support
this.
"During these challenging times, I continue to be inspired by
our people, confident in the resiliency and effectiveness of our
strategic Blueprint, and more optimistic than ever in achieving our
long-term goals," concluded Mr. McCain.
Second Quarter 2021 Highlights
- Total Company sales up 5.9% to $1,158.9
million, with an Adjusted Earnings Before Interest, Taxes,
Depreciation and Amortization ("EBITDA")(i)
Margin of 9.0%, similar to the performance in the first
quarter.
- Meat Protein Group sales up 7.4% to $1,117.5 million, while Adjusted EBITDA Margin
remained healthy at 11.6%.
- Excluding foreign exchange impacts, Plant Protein Group sales
declined 10.4% while selling, general and administrative
("SG&A") expenses were similar to last year.
- Net earnings were $8.8 million,
compared to $25.7 million last year
primarily due to non-cash fair value changes in biological assets
and derivative contracts.
- Capital expenditures were $166.8
million and consisted predominantly of Construction
Capital(i) of $127.8
million, the majority of which was related to ongoing
construction of the London,
Ontario poultry facility.
- Balance sheet remained strong with Net Debt of $1,068.2 million and undrawn committed credit of
over $800 million.
- 2021 Outlook: Meat Protein Group targets unchanged –
mid-to-high single digit sales growth and Adjusted EBITDA Margin
expansion; Plant Protein sales growth now expected to be at least
30% in the back half of 2021.
(i)
|
Refer to the
section titled Non-IFRS Financial Measures in this news
release.
|
Financial Highlights
|
|
|
|
|
|
|
As at or for
the
|
Measure(i)
(Unaudited)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|
2021
|
|
2020
|
|
Change
|
|
2021
|
|
2020
|
|
Change
|
Sales
|
|
$
|
1,158.9
|
|
$
|
1,094.6
|
|
5.9
|
%
|
|
$
|
2,211.9
|
|
$
|
2,117.3
|
|
4.5
|
%
|
Net Earnings
|
|
$
|
8.8
|
|
$
|
25.7
|
|
(65.8)
|
%
|
|
$
|
56.5
|
|
$
|
21.9
|
|
157.3
|
%
|
Basic Earnings per
Share
|
|
$
|
0.07
|
|
$
|
0.21
|
|
(66.7)
|
%
|
|
$
|
0.46
|
|
$
|
0.18
|
|
155.6
|
%
|
Adjusted Operating
Earnings(ii)
|
|
$
|
56.4
|
|
$
|
66.7
|
|
(15.4)
|
%
|
|
$
|
106.7
|
|
$
|
111.8
|
|
(4.5)
|
%
|
Adjusted Earnings per
Share(ii)
|
|
$
|
0.28
|
|
$
|
0.35
|
|
(20.0)
|
%
|
|
$
|
0.54
|
|
$
|
0.56
|
|
(3.6)
|
%
|
Adjusted EBITDA - Meat
Protein Group(ii)
|
|
$
|
129.7
|
|
$
|
138.2
|
|
(6.2)
|
%
|
|
$
|
253.0
|
|
$
|
249.3
|
|
1.5
|
%
|
Sales - Plant Protein
Group
|
|
$
|
48.1
|
|
$
|
60.6
|
|
(20.6)
|
%
|
|
$
|
90.7
|
|
$
|
107.0
|
|
(15.2)
|
%
|
Free Cash
Flow(ii)
|
|
$
|
(135.9)
|
|
$
|
53.7
|
|
(353.1)
|
%
|
|
$
|
(331.1)
|
|
$
|
(79.6)
|
|
(316.0)
|
%
|
Construction
Capital(ii)
|
|
|
|
|
|
|
|
|
$
|
720.8
|
|
$
|
229.0
|
|
214.8
|
%
|
Net
Debt(ii)
|
|
|
|
|
|
|
|
|
$
|
(1,068.2)
|
|
$
|
(606.7)
|
|
76.1
|
%
|
(i)
|
All financial
measures in millions of dollars except Basic and Adjusted Earnings
per Share.
|
(ii)
|
Refer to the
section titled Non-IFRS Financial Measures in this news
release.
|
Sales for the second quarter of 2021 were $1,158.9 million compared to $1,094.6 million last year, an increase of 5.9%,
driven by higher sales in the Meat Protein Group, partially offset
by lower sales in the Plant Protein Group. For more details on
sales performance by operating segment, please refer to the section
titled Operating Review.
Year-to-date sales for 2021 were $2,211.9
million compared to $2,117.3
million last year, an increase of 4.5%, due to similar
factors as noted above.
Net earnings for the second quarter of 2021 were $8.8 million ($0.07
per basic share) compared to $25.7
million ($0.21 per basic
share) last year. The reduction in net earnings was primarily
driven by a higher net loss of $31.7
million (2020: net loss of $17.2
million) from non-cash fair value changes in biological
assets and derivative contracts, which are both excluded in the
calculation of Adjusted Operating Earnings below. Results were also
impacted by limited access to China and lower primary processing margins in
the Meat Protein Group, as well as lower sales volume and capacity
utilization in the Plant Protein Group.
Year-to-date net earnings for 2021 were $56.5 million ($0.46 per basic share) compared to $21.9 million ($0.18 per basic share) last year. The increase
was primarily driven by a lower net loss of $4.9 million (2020: net loss of $53.9 million) from non-cash fair value changes
in biological assets and derivative contracts, which are both
excluded in the calculation of Adjusted Operating Earnings
below.
Adjusted Operating Earnings for the second quarter of 2021 were
$56.4 million compared to
$66.7 million last year, and Adjusted
Earnings per Share for the second quarter of 2021 were $0.28 compared to $0.35 last year due to similar factors as noted
above.
Year-to-date Adjusted Operating Earnings for 2021 were
$106.7 million compared to
$111.8 million last year, and
Adjusted Earnings per Share for 2021 were $0.54 compared to $0.56 last year due to similar factors as noted
above.
For further discussion on key metrics and a discussion of
results by operating segment, refer to the section titled Operating
Review.
Note: Several items are excluded from the discussions of
underlying earnings performance as they are not representative of
ongoing operational activities. Refer to the section entitled
Non-IFRS Financial Measures at the end of this news release for a
description and reconciliation of all non-IFRS financial
measures.
Response to COVID-19
As an essential service, Maple Leaf Foods is focused on
protecting the health and well-being of its people, maintaining
business continuity, and broadening its social outreach. To manage
through this unprecedented environment, the Company has taken a
number of measures in its business and operating practices that
include heightened safety policies and procedures, and close
communication and collaboration with public health authorities
including on-site vaccination clinics. The measures enacted to
protect the health and safety of employees have increased the
Company's cost structure due to higher labour, personal protective
equipment, sanitation and other expenses associated with the
pandemic. Continuing COVID-19 structural costs have been
incorporated in the Company's 2021 operating plan.
Overall, the Company believes its proactive and comprehensive
efforts have, and should continue to mitigate adverse operational
impacts. As the COVID-19 situation evolves, Maple Leaf Foods will
continue to adapt and adopt best practices that prioritize the
health and safety of its employees and the stability of the food
supply. As part of Maple Leaf Foods' broader social responsibility
since the pandemic began, the Company has provided extensive
support to front-line staff, emergency food relief efforts and
health care providers.
Operating Review
The Company has two reportable segments. These segments offer
different products, with separate organizational structures,
brands, financial and marketing strategies. The Company's chief
operating decision makers regularly review internal reports for
these businesses: performance of the Meat Protein Group is based on
revenue growth, Adjusted Operating Earnings and Adjusted EBITDA,
while the performance of the Plant Protein Group is based
predominantly on revenue growth rates, gross margin optimization
and controlling SG&A investment levels, which generate high
revenue growth rates.
The following table summarizes the Company's sales, gross
profit, SG&A expenses, Adjusted Operating Earnings, Adjusted
EBITDA, and Adjusted EBITDA Margin by operating segment for the
three months ended June 30, 2021 and June 30, 2020.
|
Three months ended
June 30, 2021
|
Three months ended
June 30, 2020
|
($
millions)(i)
(Unaudited)
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
|
1,117.5
|
48.1
|
(6.7)
|
$
|
1,158.9
|
$
|
1,040.4
|
60.6
|
(6.4)
|
$
|
1,094.6
|
Gross
profit
|
$
|
167.0
|
0.3
|
(31.7)
|
$
|
135.7
|
$
|
176.6
|
7.9
|
(17.2)
|
$
|
167.3
|
Selling, general
and administrative
expenses
|
$
|
81.2
|
29.8
|
—
|
$
|
110.9
|
$
|
83.7
|
34.1
|
—
|
$
|
117.8
|
Adjusted Operating
Earnings(iii)
|
$
|
85.9
|
(29.5)
|
—
|
$
|
56.4
|
$
|
92.9
|
(26.3)
|
—
|
$
|
66.7
|
Adjusted
EBITDA(iii)
|
$
|
129.7
|
(25.9)
|
—
|
$
|
103.8
|
$
|
138.2
|
(22.6)
|
—
|
$
|
115.7
|
Adjusted EBITDA
Margin(iii)
|
11.6%
|
(53.9)%
|
n/a
|
9.0%
|
13.3%
|
(37.2)%
|
n/a
|
10.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological assets and
derivatives, and non-allocated costs which are comprised of
expenses not separately identifiable to reportable segments and are
not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the
section titled Non-IFRS Financial Measures in this news
release.
|
The following table summarizes the Company's sales, gross
profit, SG&A expenses, Adjusted Operating Earnings, Adjusted
EBITDA, and Adjusted EBITDA Margin by operating segment for the six
months ended June 30, 2021 and June 30, 2020.
|
Six months ended
June 30, 2021
|
Six months ended June
30, 2020
|
($
millions)(i) (Unaudited)
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
|
2,131.2
|
90.7
|
|
(9.9)
|
$
|
2,211.9
|
$
|
2,021.7
|
107.0
|
(11.4)
|
$
|
2,117.3
|
Gross
profit
|
$
|
333.1
|
0.4
|
(4.9)
|
$
|
328.6
|
$
|
333.9
|
14.6
|
(53.9)
|
$
|
294.7
|
Selling, general
and administrative
expenses
|
$
|
168.3
|
58.6
|
—
|
$
|
226.8
|
$
|
171.8
|
65.0
|
—
|
$
|
236.7
|
Adjusted Operating
Earnings(iii)
|
$
|
164.9
|
(58.1)
|
—
|
$
|
106.7
|
$
|
162.1
|
(50.3)
|
—
|
$
|
111.8
|
Adjusted
EBITDA(iii)
|
$
|
253.0
|
(50.9)
|
—
|
$
|
202.1
|
$
|
249.3
|
(43.1)
|
—
|
$
|
206.2
|
Adjusted EBITDA
Margin(iii)
|
11.9%
|
(56.1)%
|
n/a
|
9.1%
|
12.3%
|
(40.3)%
|
n/a
|
9.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological assets and
derivatives, and non-allocated costs which are comprised of
expenses not separately identifiable to reportable segments and are
not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the
section titled Non-IFRS Financial Measures in this news
release.
|
Meat Protein Group
The Meat Protein Group is comprised of prepared meats,
ready-to-cook and ready-to-serve meals, value-added fresh pork and
poultry products that are sold to retail, foodservice and
industrial channels, and agricultural operations in pork and
poultry. The Meat Protein Group includes leading brands such as
Maple Leaf®, Maple Leaf Prime®, Schneiders®, Mina®, Greenfield
Natural Meat Co.® and many leading regional brands.
Sales for the second quarter of 2021 increased 7.4% to
$1,117.5 million compared to
$1,040.4 million last year. Sales
growth was driven by higher fresh pork and poultry market values,
favourable mix-shift towards branded products and sustainable
meats, and higher volumes in the U.S. These factors more than
offset an unfavourable impact from foreign exchange. Strong
recovery in foodservice volumes offset normalization in retail
volumes from the initial pandemic onset.
Year-to-date sales for 2021 increased 5.4% to $2,131.2 million compared to $2,021.7 million last year. Sales growth was
driven by higher fresh pork and poultry market values, favourable
mix-shift from branded products and sustainable meats, U.S. volume
and prepared meats pricing action taken in the fourth quarter of
2020 to mitigate inflation and other structural cost increases.
These factors more than offset an unfavourable impact from foreign
exchange and lower sales to China.
Strong recovery in foodservice volumes during the second quarter
offset normalization in retail volumes.
Gross profit for the second quarter of 2021 was $167.0 million (gross margin of 14.9%) compared
to $176.6 million (gross margin of
17.0%) last year. Mix-shift benefits towards growth in branded
products and sustainable meats were more than offset by limited
access to China and lower margins
in primary processing. Gross profit in the second quarter of 2020
was also impacted by significant operational and one-off costs in
response to COVID-19.
Year-to-date gross profit for 2021 was $333.1 million (gross margin of 15.6%) compared
to $333.9 million (gross margin of
16.5%) last year. Strong operational performance and mix-shift
benefits from branded products and sustainable meats were offset by
limited access to China. Gross
profit in the first half of 2020 was also impacted by significant
operational and one-off costs in response to COVID-19.
SG&A expenses for the second quarter of 2021 were
$81.2 million compared to
$83.7 million last year. The
reduction in SG&A expenses was driven by a decrease in variable
compensation, partially offset by the normalization of advertising
and promotions spend compared to last year. Other discretionary
spending accounts, such as travel and training were similar to last
year.
Year-to-date SG&A expenses for 2021 were $168.3 million compared to $171.8 million last year. The reduction in
SG&A was driven by a decrease in variable compensation, and the
lapping of donations made in March
2020 to support front-line health care workers at the outset
of the COVID-19 pandemic. This more than offset the normalization
of advertising and promotions as well as higher personnel
costs.
Adjusted Operating Earnings for the second quarter of 2021 were
$85.9 million compared to
$92.9 million last year, consistent
with factors noted above.
Year-to-date Adjusted Operating Earnings for 2021 were
$164.9 million compared to
$162.1 million last year, consistent
with factors noted above.
Adjusted EBITDA for the second quarter of 2021 were $129.7 million compared to $138.2 million last year, driven by factors
consistent with those noted above. Adjusted EBITDA Margin for the
second quarter was 11.6% compared to 13.3% last year, also driven
by factors consistent with those noted above.
Year-to-date Adjusted EBITDA for 2021 were $253.0 million compared to $249.3 million last year, driven by factors
consistent with those noted above. Year-to-date Adjusted EBITDA
Margin for 2021 was 11.9% compared to 12.3% last year, also driven
by factors consistent with those noted above.
Plant Protein Group
The Plant Protein Group is comprised of refrigerated plant
protein products, premium grain-based protein, and vegan cheese
products sold to retail, foodservice and industrial channels. The
Plant Protein Group includes the leading brands Lightlife® and
Field Roast™.
Sales for the second quarter of 2021 decreased 20.7% to
$48.1 million compared to
$60.6 million last year. Excluding
the impact of foreign exchange, sales decreased 10.4%, driven by
lower retail volumes as the business lapped surge demand in 2020
tied to COVID-19. This more than offset higher foodservice volumes
and pricing action implemented in the fourth quarter of 2020 to
mitigate inflation and structural cost increases.
Year-to-date sales for 2021 decreased 15.2% to $90.7 million compared to $107.0 million last year. Excluding the impact of
foreign exchange, sales were down 6.9%, driven by lower volumes in
fresh retail products. This more than offset pricing action
implemented in the fourth quarter of 2020 to mitigate inflation and
structural cost increases.
Gross profit for the second quarter of 2021 was $0.3 million (gross margin of 0.6%) compared to
$7.9 million (gross margin of 13.0%)
last year. The decrease in gross profit was attributed to strategic
investments in capacity to build for anticipated demand, which has
resulted in increased overhead and transitory costs. Other factors
include lower sales volumes and higher trade expenditures. The
second quarter of 2020 was also impacted by significant operational
and one-off costs in response to COVID-19.
Year-to-date gross profit for 2021 was $0.4 million (gross margin of 0.5%) compared to
$14.6 million (gross margin of 13.7%)
last year. The decrease in gross profit was attributed to lower
sales volumes and capacity utilization, as well as higher trade
expenditure. Gross profit in the first half of 2020 was also
impacted by significant operational and one-off costs in response
to COVID-19.
SG&A expenses for the second quarter of 2021 were
$29.8 million (61.9% of sales)
compared to $34.1 million (56.3% of
sales) last year. The decrease in SG&A expenses was primarily
driven by the impact of foreign exchange. Excluding this, spend was
similar to last year as lower variable compensation was offset by
increased expenses related to organizational capacity.
Year-to-date SG&A expenses for 2021 were $58.6 million (64.6% of sales) compared to
$65.0 million (60.7% of sales) last
year. The decrease in SG&A expenses was primarily driven by the
impact of foreign exchange. Excluding this, spend was similar to
last year as lower advertising and promotion costs were offset by
increased expenses related to organizational capacity.
Adjusted Operating Earnings for the second quarter of 2021 were
a loss of $29.5 million compared to a
loss of $26.3 million last year. The
decline in Adjusted Operating Earnings is consistent with the
factors noted above.
Year-to-date Adjusted Operating Earnings for 2021 were a loss of
$58.1 million compared to a loss of
$50.3 million last year. The decline
in Adjusted Operating Earnings is consistent with the factors noted
above.
Other Matters
On August 4, 2021, the Board of
Directors approved a quarterly dividend of of $0.18 per share, $0.72 per share on an annual basis, payable
September 29, 2021 to shareholders of
record at the close of business September 8,
2021. Unless indicated otherwise by the Company at or before
the time the dividend is paid, the dividend will be considered an
eligible dividend for the purposes of the "Enhanced Dividend Tax
Credit System".
Conference Call
A conference call will be held at 8:00 a.m. ET on
August 5, 2021, to review Maple Leaf Foods' second quarter
financial results. To participate in the call, please dial
416-764-8650 or 1-888-664-6383. For those unable to participate,
playback will be made available an hour after the event at
416-764-8677 or 1-888-390-0541 (Passcode: 127538#).
A webcast of the second quarter conference call will also be
available at: https://www.mapleleaffoods.com
The Company's full unaudited condensed consolidated interim
financial statements ("Consolidated Interim Financial Statements")
and related Management's Discussion and Analysis are available on
the Company's website.
An investor presentation related to the Company's second quarter
financial results is available at www.mapleleaffoods.com and
can be found under Presentations and Webcasts on the
Investors page.
2021 Outlook
Throughout the COVID-19 pandemic, Maple Leaf Foods has remained
focused on protecting its employees and ensuring continuity of its
supply chain. As a result, the current environment does increase
certain operating costs and potential for short-term processing
disruptions to protect the health and safety of plant personnel.
Continuing COVID-19 structural costs have been incorporated in the
Company's 2021 operating plan.
Based on year-to-date performance and the Company's outlook for
the balance of the year, Maple Leaf Foods expects to achieve the
following in 2021:
Meat Protein Group - Driving Profitable Growth
- Mid-to-high single digit sales growth on a 52-week comparable
basis, driven by continued momentum in sustainable meats,
leveraging brand renovation, and growth into the U.S. market.
- Adjusted EBITDA margin expansion, progressing towards the 2022
target of 14% - 16%, driven by mix-shift benefits in prepared meats
resulting from growth in sustainable meats and brand renovation, as
well as operational efficiencies, while assuming pork complex
conditions in-line with the 5-year average.
Plant Protein Group - Investing for Growth
- Sales growth in the second half of the year of at least 30%,
excluding any impact from fluctuations in foreign exchange, in-line
with the Company's long-term strategic target. Growth is expected
to be driven by continued momentum in the core product line,
product innovation, improved velocities and distribution in the
fresh line and resurgence in foodservice activity which is largely
tied to the abatement of COVID-19 restrictions. Growth is expected
to accelerate as the year progresses. While the Company sees a
gradual reopening of the economy in both key markets in
North America, there is a lack of
full visibility on the potential impact of a fourth wave of
COVID-19 on the recovery of the foodservice business.
- Gross margin is expected to be volatile in the near-term, as
benefits from structural improvements in the supply chain may be
impacted by investment opportunities to drive sales growth in a
rapidly evolving market, as well as ongoing effects of
COVID-19.
- SG&A expenses broadly in-line with 2020 levels, excluding
any impact from fluctuations in foreign exchange, while declining
as a percentage of sales as the Company leverages investments in
advertising, promotion and marketing to elevate the Lightlife® and
Field Roast™ brand renovations, drive innovation and build scale in
the business.
Capital
- The Company's capital expenditure estimate for the full year of
2021 remains unchanged and in the range of $550 million to $650
million, with approximately 75% to be comprised of
Construction Capital. A significant portion of the Construction
Capital is related to the London,
Ontario poultry facility, the plant protein facility in
Indianapolis, Indiana and other
projects to add capacity and improve efficiency in our prepared
meats business.
Factors that could have an impact on the business, which cannot
be estimated or controlled due to the COVID-19 pandemic,
include:
- Volatility in the pork and poultry commodity and foreign
exchange markets.
- The balance between retail and foodservice demand.
- Potential future production disruptions or shutdowns.
- The duration of government measures, including social
distancing.
In addition to financial and operational priorities, Maple Leaf
Foods believes that shared value and operating its business for the
benefit of all stakeholders is crucial. The Company's guiding
pillars to be the "Most Sustainable Protein Company on Earth"
include Better Food, Better Care, Better Communities, Better Planet
and are core to how Maple Leaf Foods conducts itself. To that end,
the Company's priorities include:
- Better Food - leading the real food movement and
transitioning key brands to 100% "raised without antibiotics".
- Better Care - further advancement of animal care,
including progress towards transitioning all sows under management
to open housing systems by 2022.
- Better Communities - investing approximately 1% of
pre-tax profit to advance sustainable food security.
- Better Planet - continuing to amplify its commitment to
carbon neutrality, while focusing on eliminating waste in any
resources it consumes, including food, energy, water, packaging,
and time.
Non-IFRS Financial Measures
The Company uses the following non-IFRS measures: Adjusted
Operating Earnings, Adjusted Earnings per Share, Adjusted EBITDA,
Adjusted EBITDA Margin, Construction Capital, Net Debt, Free Cash
Flow and Return on Net Assets. Management believes that these
non-IFRS measures provide useful information to investors in
measuring the financial performance of the Company for the reasons
outlined below. These measures do not have a standardized meaning
prescribed by IFRS and therefore they may not be comparable to
similarly titled measures presented by other publicly traded
companies and should not be construed as an alternative to other
financial measures determined in accordance with IFRS.
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted
EBITDA Margin
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA
Margin are non-IFRS measures used by Management to evaluate
financial operating results. Adjusted Operating Earnings is defined
as earnings before income taxes and interest expense adjusted for
items that are not considered representative of ongoing operational
activities of the business and items where the economic impact of
the transactions will be reflected in earnings in future periods
when the underlying asset is sold or transferred. Adjusted EBITDA
is defined as Adjusted Operating Earnings plus depreciation and
intangible asset amortization, adjusted for items included in other
expense that are considered representative of ongoing operational
activities of the business. Adjusted EBITDA Margin is calculated as
Adjusted EBITDA divided by sales.
The tables below provide a reconciliation of earnings (loss)
before income taxes as reported under IFRS in the Consolidated
Interim Financial Statements to Adjusted Operating Earnings and
Adjusted EBITDA for the three and six months ended June 30,
2021 as indicated below. Management believes that these non-IFRS
measures are useful in assessing the performance of the Company's
ongoing operations and its ability to generate cash flows to fund
its cash requirements, including the Company's capital investment
program.
|
Three months ended
June 30, 2021
|
Three months ended
June 30, 2020
|
($
millions)(i)
(Unaudited)
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Earnings (loss)
before income taxes
|
$
|
86.7
|
(29.6)
|
(42.9)
|
$
|
14.2
|
$
|
92.8
|
(26.3)
|
(29.3)
|
$
|
37.2
|
Interest expense and
other financing costs
|
—
|
—
|
5.7
|
5.7
|
—
|
—
|
8.1
|
8.1
|
Other (income)
expense
|
(2.0)
|
0.1
|
5.5
|
3.6
|
(1.4)
|
—
|
4.1
|
2.7
|
Restructuring and
other related costs
|
1.2
|
—
|
—
|
1.2
|
1.5
|
—
|
—
|
1.5
|
Earnings (loss)
from operations
|
$
|
85.9
|
(29.5)
|
(31.7)
|
$
|
24.7
|
$
|
92.9
|
(26.3)
|
(17.2)
|
$
|
49.5
|
Decrease in fair
value of biological assets
|
—
|
—
|
51.9
|
51.9
|
—
|
—
|
26.7
|
26.7
|
Unrealized gain on
derivative contracts
|
—
|
—
|
(20.2)
|
(20.2)
|
—
|
—
|
(9.5)
|
(9.5)
|
Adjusted Operating
Earnings
|
$
|
85.9
|
(29.5)
|
—
|
$
|
56.4
|
$
|
92.9
|
(26.3)
|
—
|
$
|
66.7
|
Depreciation and
amortization
|
45.8
|
3.7
|
—
|
49.4
|
44.0
|
3.7
|
—
|
47.7
|
Items included in
other expense representative
of
ongoing operations(iii)
|
(1.9)
|
(0.1)
|
—
|
(2.0)
|
1.4
|
—
|
—
|
1.3
|
Adjusted
EBITDA
|
$
|
129.7
|
(25.9)
|
—
|
$
|
103.8
|
$
|
138.2
|
(22.6)
|
—
|
$
|
115.7
|
Adjusted EBITDA
Margin
|
11.6%
|
(53.9)%
|
n/a
|
9.0%
|
13.3%
|
(37.2)%
|
n/a
|
10.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Totals may not add
due to rounding.
|
|
|
(ii)
|
Non-Allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of expenses
not separately identifiable to reportable segments and are not part
of the measures used by the Company when assessing a segment's
operating results.
|
|
|
(iii)
|
Primarily includes
gain/loss on sale of long-term assets and other miscellaneous
expenses.
|
|
|
|
Six months ended
June 30, 2021
|
Six months ended June
30, 2020
|
($
millions)(i) (Unaudited)
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat Protein
Group
|
Plant Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Earnings (loss)
before income taxes
|
$
|
162.9
|
(58.3)
|
(24.5)
|
$
|
80.1
|
$
|
161.0
|
(50.4)
|
(76.5)
|
$
|
34.2
|
Interest expense and
other financing costs
|
—
|
—
|
10.7
|
10.7
|
—
|
—
|
16.0
|
16.0
|
Other (income)
expense
|
(0.9)
|
0.2
|
8.9
|
8.2
|
(0.2)
|
—
|
6.7
|
6.5
|
Restructuring and
other related costs
|
2.9
|
—
|
—
|
2.9
|
1.3
|
—
|
—
|
1.3
|
Earnings (loss)
from operations
|
$
|
164.9
|
(58.1)
|
(4.9)
|
$
|
101.8
|
$
|
162.1
|
(50.3)
|
(53.9)
|
$
|
57.9
|
Decrease in fair
value of biological assets
|
—
|
—
|
13.4
|
13.4
|
—
|
—
|
41.3
|
41.3
|
Unrealized (gain)
loss on derivative contracts
|
—
|
—
|
(8.5)
|
(8.5)
|
—
|
—
|
12.5
|
12.5
|
Adjusted Operating
Earnings
|
$
|
164.9
|
(58.1)
|
—
|
$
|
106.7
|
$
|
162.1
|
(50.3)
|
—
|
$
|
111.8
|
Depreciation and
amortization
|
91.2
|
7.4
|
—
|
98.7
|
87.0
|
7.3
|
—
|
94.2
|
Items included in
other expense representative
of
ongoing operations(iii)
|
(3.1)
|
(0.2)
|
—
|
(3.3)
|
0.2
|
—
|
—
|
0.2
|
Adjusted
EBITDA
|
$
|
253.0
|
(50.9)
|
—
|
$
|
202.1
|
$
|
249.3
|
(43.1)
|
—
|
$
|
206.2
|
Adjusted EBITDA
Margin
|
11.9%
|
(56.1)%
|
n/a
|
9.1%
|
12.3%
|
(40.3)%
|
n/a
|
9.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Totals may not add
due to rounding.
|
|
|
(ii)
|
Non-Allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of expenses
not separately identifiable to reportable segments and are not part
of the measures used by the Company when assessing a segment's
operating results.
|
|
|
(iii)
|
Primarily includes
gain/loss on sale of long-term assets and other miscellaneous
expenses.
|
Adjusted Earnings per Share
Adjusted Earnings per Share, a non-IFRS measure, is used by
Management to evaluate financial operating results. It is defined
as basic earnings per share and is adjusted on the same basis as
Adjusted Operating Earnings. The table below provides a
reconciliation of basic earnings per share as reported under IFRS
in the Consolidated Interim Financial Statements to Adjusted
Earnings per Share for the three months ended June 30, as indicated below. Management believes
this basis is the most appropriate on which to evaluate financial
results as they are representative of the ongoing operations of the
Company.
($ per
share) (Unaudited)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
2021
|
2020
|
2021
|
2020
|
Basic earnings per
share
|
|
$
|
0.07
|
|
$
|
0.21
|
|
$
|
0.46
|
|
$
|
0.18
|
Restructuring and
other related costs(i)
|
|
0.01
|
|
0.01
|
|
0.02
|
|
0.01
|
Items included in
other expense not considered representative of ongoing
operations(ii)
|
|
0.02
|
|
0.03
|
|
0.04
|
|
0.05
|
Change in fair value
of biological assets
|
|
0.31
|
|
0.16
|
|
0.08
|
|
0.25
|
Unrealized (gain)
loss on derivatives
|
|
(0.12)
|
|
(0.06)
|
|
(0.05)
|
|
0.07
|
Adjusted Earnings
per Share(iii)
|
|
$
|
0.28
|
|
$
|
0.35
|
|
$
|
0.54
|
|
$
|
0.56
|
(i)
|
Includes per share
impact of restructuring and other related costs, net of
tax.
|
(ii)
|
Primarily includes
legal fees and provisions and transaction related costs, net of
tax.
|
(iii)
|
Totals may not add
due to rounding.
|
Construction Capital
Construction Capital, a non-IFRS measure, is used by Management
to evaluate the amount of capital resources invested in specific
strategic development projects that have not yet entered commercial
production. It is defined as investments and related financing
charges in projects over $50.0
million that are related to longer-term strategic
initiatives, with no returns expected for at least 12 months in the
future and the asset will be re-categorized from Construction
Capital once operational. Current strategic initiatives primarily
include the investments in the London,
Ontario poultry production facility, further capacity and
efficiency improvements in the prepared meats business, investments
in plant protein capacity at the Walker Drive facility in
Brampton, Ontario, and the plant
protein production facilities in Indiana. The following table is a summary of
Construction Capital activity and debt financing for the periods
indicated below.
($
thousands)
(Unaudited)
|
|
As at June
30,
|
|
2021
|
|
2020
|
Opening balance at
January 1
|
|
$
|
440,590
|
|
$
|
106,831
|
Additions
|
|
148,520
|
|
56,926
|
Interest paid and
capitalized on construction capital(i)
|
|
3,821
|
|
871
|
Balance at March
31
|
|
$
|
592,931
|
|
$
|
164,628
|
Additions
|
|
123,275
|
|
62,760
|
Interest paid and
capitalized on construction capital(i)
|
|
4,547
|
|
1,596
|
Balance at June
30
|
|
$
|
720,753
|
|
$
|
228,984
|
Construction
Capital debt financing(ii)
|
|
$
|
703,502
|
|
$
|
224,897
|
|
|
(i)
|
Certain comparatives
figures have been restated to conform with current year
presentations.
|
(ii)
|
Assumed to be fully
funded by debt to the extent that the Company has Net Debt
outstanding.
|
Net Debt
The following table reconciles Net Debt to amounts reported
under IFRS in the Company's Consolidated Interim Financial
Statements as at June 30, as
indicated below. The Company calculates Net Debt as cash and cash
equivalents, less long-term debt and bank indebtedness. Management
believes this measure is useful in assessing the amount of
financial leverage employed.
($
thousands)
|
As at June
30,
|
(Unaudited)
|
2021
|
2020
|
Cash and cash
equivalents
|
|
$
|
58,878
|
|
$
|
111,229
|
Current portion of
long-term debt
|
|
$
|
(5,235)
|
|
$
|
(924)
|
Long-term
debt
|
|
(1,121,865)
|
|
(716,986)
|
Total
debt
|
|
$
|
(1,127,100)
|
|
$
|
(717,910)
|
Net
Debt
|
|
$
|
(1,068,222)
|
|
$
|
(606,681)
|
Free Cash Flow
Free Cash Flow, a non-IFRS measure, is used by Management to
evaluate cash flow after investing in the maintenance or expansion
of the Company's asset base. It is defined as cash provided by
operations, less cash additions to long-term assets and capitalized
interest. The following table calculates Free Cash Flow for the
periods indicated below:
($
thousands)
(Unaudited)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|
2021
|
|
2020
|
|
2021
|
|
2020
|
Cash provided by
(used in) operating activities
|
|
$
|
29,971
|
|
$
|
147,139
|
|
$
|
(263)
|
|
$
|
101,342
|
Additions to
long-term assets
|
|
(161,273)
|
|
(91,626)
|
|
(322,240)
|
|
(177,918)
|
Interest paid and
capitalized(i)
|
|
(4,638)
|
|
(1,816)
|
|
(8,609)
|
|
(3,011)
|
Free Cash
Flow
|
|
$
|
(135,940)
|
|
$
|
53,697
|
|
$
|
(331,112)
|
|
$
|
(79,587)
|
|
|
(i)
|
Certain comparatives
figures have been restated to conform with current year
presentations.
|
Return on Net Assets
Return on Net Assets ("RONA") is calculated by dividing tax
effected earnings from operations (adjusted for items which are not
considered representative of the underlying operations of the
business) by average monthly net assets. Net assets are defined as
total assets (excluding cash and deferred tax assets) less
non-interest bearing liabilities (excluding deferred tax
liabilities). Management believes that RONA is an appropriate basis
upon which to evaluate long-term financial performance.
Forward-Looking Statements
This document contains, and the Company's oral and written
public communications often contain, "forward-looking information"
within the meaning of applicable securities law. These statements
are based on current expectations, estimates, projections, beliefs,
judgments and assumptions based on information available at the
time the applicable forward-looking statement was made and in light
of the Company's experience combined with its perception of
historical trends. Such statements include, but are not limited to,
statements with respect to objectives and goals, in addition to
statements with respect to beliefs, plans, targets, goals,
objectives, expectations, anticipations, estimates, and intentions.
Forward-looking statements are typically identified by words such
as "anticipate", "continue", "estimate", "expect", "may", "will",
"project", "should", "could", "would", "believe", "plan", "intend",
"design", "target", "undertake", "view", "indicate", "maintain",
"explore", "entail", "schedule", "objective", "strategy", "likely",
"potential", "outlook", "aim", "propose", "goal", and similar
expressions suggesting future events or future performance. These
statements are not guarantees of future performance and involve
assumptions, risks and uncertainties that are difficult to
predict.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or events to differ materially from those
anticipated in such forward-looking statements. The Company
believes the expectations reflected in the forward-looking
statements are reasonable, but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon.
Specific forward-looking information in this document may
include, but is not limited to, statements with respect to:
- implications of COVID-19;
- future performance, including future financial objectives,
goals and targets, expected capital spend and expected SG&A
expenditures for the Company and each of its operating
segments;
- the execution of the Company's business strategy, including the
development and expected timing of business initiatives, brand
expansion and repositioning, and other growth opportunities, as
well as the impact thereof;
- the impact of international trade conditions on the Company's
business, including access to markets, implications associated with
the spread of foreign animal disease (such as African Swine Fever
("ASF")), and other social, economic and political factors that
affect trade;
- competitive conditions and the Company's ability to position
itself competitively in the markets in which it competes;
- capital projects, including planning, construction, estimated
expenditures, schedules, approvals, expected capacity, in-service
dates and anticipated benefits of construction of new facilities
and expansions of existing facilities;
- the Company's dividend policy, including future levels and
sustainability of cash dividends, the tax treatment thereof and
future dividend payment dates;
- the impact of commodity prices on the Company's operations and
financial performance, including the use and effectiveness of
hedging instruments;
- expected future cash flows and the sufficiency thereof, sources
of capital at attractive rates, future contractual obligations,
future financing options, renewal of credit facilities, and
availability of capital to fund growth plans, operating obligations
and dividends;
- operating risks, including the execution, monitoring and
continuous improvement of the Company's food safety programs,
animal health initiatives and cost reduction initiatives;
- the implementation, cost and impact of environmental
sustainability initiatives, as well as the anticipated future cost
of remediating environmental liabilities;
- the adoption of new accounting standards and the impact of such
adoption on the financial position of the Company;
- expectations regarding pension plan performance, including
future pension plan assets, liabilities and contributions; and
- developments and implications of actual or potential legal
actions.
Various factors or assumptions are typically applied by the
Company in drawing conclusions or making the forecasts,
projections, predictions or estimations set out in the
forward-looking statements. These factors and assumptions are based
on information currently available to the Company, including
information obtained by the Company from third-party sources and
include but are not limited to the following:
- expectations regarding the impact and future implications of
COVID-19 and adaptations in operations, customer and consumer
behaviour, economic patterns and international trade;
- the competitive environment, associated market conditions and
market share metrics, the expected behaviour of competitors and
customers and trends in consumer preferences;
- the success of the Company's business strategy, including
execution of the strategy in each of the Meat Protein and Plant
Protein Groups;
- prevailing commodity prices, interest rates, tax rates and
exchange rates;
- the economic condition of and the socio-political dynamics
between Canada, the U.S.,
Japan and China, and the ability of the Company to
access markets in these countries;
- the spread of foreign animal disease (including ASF),
preparedness strategies to manage such spread, and implications for
all protein markets;
- the availability of capital to fund future capital requirements
associated with existing operations, assets and projects;
- expectations regarding participation in and funding of the
Company's pension plans;
- the availability of insurance coverage to manage certain
liability exposures;
- the extent of future liabilities and recoveries related to
legal claims;
- prevailing regulatory, tax and environmental laws; and
- future operating costs and performance, including the Company's
ability to achieve operating efficiencies and maintain high sales
volumes, high turnover of inventories and high turnover of accounts
receivable.
Readers are cautioned that these assumptions may prove to be
incorrect in whole or in part. The Company's actual results may
differ materially from those anticipated in any forward-looking
statements.
Factors that could cause actual results or outcomes to differ
materially from the results expressed, implied, or projected in the
forward-looking statements contained in this document include,
among other things, risks associated with the following:
- implications of COVID-19 on the operations and financial
performance of the Company, as well the implications for macro
socio-economic trends;
- competition, market conditions and the activities of
competitors and customers;
- food safety, consumer liability and product recalls;
- the health status of livestock, including the impact of
potential pandemics;
- international trade and access to markets, as well as social,
political and economic dynamics affecting same;
- availability of and access to capital;
- decision respecting the return of capital to shareholders;
- the execution of capital projects, including cost, schedule and
regulatory variables;
- cyber security and the maintenance and operation of the
Company's information systems and processes;
- acquisitions and divestitures;
- climate change;
- fluctuations in the debt and equity markets;
- fluctuations in interest rates and currency exchange
rates;
- pension assets and liabilities;
- cyclical nature of the cost and supply of hogs and the
competitive nature of the pork market generally;
- the effectiveness of commodity and interest rate hedging
strategies;
- impact of changes in the market value of the biological assets
and hedging instruments;
- the supply management system for poultry in Canada;
- availability of plant protein ingredients;
- intellectual property, including product innovation, product
development, brand strategy and trademark protection;
- consolidation of operations and focus on protein;
- the use of contract manufacturers;
- reputation;
- weather;
- compliance with government regulation and adapting to changes
in laws;
- actual and threatened legal claims;
- consumer trends and changes in consumer tastes and buying
patterns;
- environmental regulation and potential environmental
liabilities;
- consolidation in the retail environment;
- employment matters, including complying with employment laws
across multiple jurisdictions, the potential for work stoppages due
to non-renewal of collective agreements, recruiting and retaining
qualified personnel, reliance on key personnel and succession
planning;
- pricing of products;
- managing the Company's supply chain;
- changes in International Financial Reporting Standards and
other accounting standards that the Company is required to adhere
to for regulatory purposes; and
- other factors as set out under the heading "Risk Factors" in
the Company's Management Discussion and Analysis for the year ended
December 31, 2020.
The Company cautions readers that the foregoing list of factors
is not exhaustive.
Readers are further cautioned that some of the forward-looking
information, such as statements concerning future capital
expenditures, Adjusted EBITDA Margin growth in the Meat Protein
Group, expected sales and growth margin targets in the Plant
Protein Group and SG&A spend, may be considered to be financial
outlooks for purposes of applicable securities legislation. These
financial outlooks are presented to evaluate potential future
earnings and anticipated future uses of cash flows and may not be
appropriate for other purposes. Readers should not assume these
financial outlooks will be achieved.
More information about risk factors can be found under the
heading "Risk Factors" in the Company's Annual Management's
Discussion and Analysis for the year ended December 31, 2020, that is available on SEDAR at
www.sedar.com. The reader should review such section in detail.
Additional information concerning the Company, including the
Company's Annual Information Form, is available on SEDAR at
www.sedar.com.
All forward-looking statements included herein speak only as of
the date hereof. Unless required by law, the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. All forward-looking statements
contained herein are expressly qualified by this cautionary
statement.
About Maple Leaf Foods Inc.
Maple Leaf Foods is a carbon neutral company with a vision to be
the most sustainable protein company on earth, responsibly
producing food products under leading brands including Maple Leaf®,
Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®,
Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®,
Lightlife® and Field Roast™. The Company employs
approximately 13,500 people and does business primarily in
Canada, the U.S. and Asia. The Company is headquartered in
Mississauga, Ontario and its
shares trade on the Toronto Stock Exchange (MFI).
Consolidated Interim Balance Sheets
(In thousands of
Canadian dollars)
(Unaudited)
|
As at June
30,
2021
|
As at June 30,
2020
|
As at December 31,
2020
|
ASSETS
|
|
|
(Audited)
|
Current
assets
|
|
|
|
Cash and cash
equivalents
|
$
|
58,878
|
$
|
111,229
|
$
|
100,828
|
Accounts
receivable
|
201,027
|
163,753
|
159,750
|
Notes
receivable
|
66,297
|
33,783
|
31,550
|
Inventories
|
442,152
|
422,308
|
398,070
|
Biological
assets
|
118,445
|
78,249
|
125,648
|
Income taxes
recoverable
|
1,830
|
—
|
1,830
|
Prepaid expenses and
other assets
|
52,810
|
43,653
|
64,517
|
Assets held for
sale
|
—
|
34,167
|
575
|
|
$
|
941,439
|
$
|
887,142
|
$
|
882,768
|
Property and
equipment
|
2,011,453
|
1,512,093
|
1,721,487
|
Right-of-use
assets
|
180,579
|
237,618
|
222,705
|
Investments
|
15,370
|
17,076
|
15,910
|
Other long-term
assets
|
8,851
|
10,638
|
9,568
|
Deferred tax
asset
|
24,775
|
—
|
14,070
|
Goodwill
|
647,772
|
664,598
|
652,501
|
Intangible
assets
|
373,663
|
356,323
|
341,196
|
Total
assets
|
$
|
4,203,902
|
$
|
3,685,488
|
$
|
3,860,205
|
LIABILITIES AND
EQUITY
|
|
|
|
Current
liabilities
|
|
|
|
Accounts payable and
accruals
|
$
|
499,099
|
$
|
436,794
|
$
|
501,529
|
Current portion of
provisions
|
886
|
3,247
|
1,529
|
Current portion of
long-term debt
|
5,235
|
924
|
900
|
Current portion of
lease obligations
|
40,276
|
42,295
|
79,601
|
Income taxes
payable
|
14,396
|
11,060
|
27,639
|
Other current
liabilities
|
59,862
|
40,651
|
55,849
|
|
$
|
619,754
|
$
|
534,971
|
$
|
667,047
|
Long-term
debt
|
1,121,865
|
716,986
|
745,048
|
Lease
obligations
|
154,457
|
212,871
|
160,636
|
Employee
benefits
|
90,879
|
180,597
|
188,946
|
Provisions
|
44,555
|
43,202
|
44,230
|
Other long-term
liabilities
|
6,022
|
19,768
|
11,918
|
Deferred tax
liability
|
140,957
|
91,067
|
109,916
|
Total
liabilities
|
$
|
2,178,489
|
$
|
1,799,462
|
$
|
1,927,741
|
|
|
|
|
Shareholders'
equity
|
|
|
|
Share
capital
|
$
|
840,230
|
$
|
844,700
|
$
|
838,969
|
Retained
earnings
|
1,210,225
|
1,075,805
|
1,124,973
|
Contributed
surplus
|
3,186
|
3,240
|
5,866
|
Accumulated other
comprehensive loss
|
(9,490)
|
(13,789)
|
(13,414)
|
Treasury
stock
|
(18,738)
|
(23,930)
|
(23,930)
|
Total shareholders'
equity
|
$
|
2,025,413
|
$
|
1,886,026
|
$
|
1,932,464
|
Total liabilities and
equity
|
$
|
4,203,902
|
$
|
3,685,488
|
$
|
3,860,205
|
Consolidated Interim Statements of Net Earnings
(In thousands of
Canadian dollars, except share amounts)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
(Unaudited)
|
2021
|
2020
|
2021
|
2020
|
|
|
|
|
|
|
Sales
|
|
$
|
1,158,861
|
$
|
1,094,574
|
$
|
2,211,944
|
$
|
2,117,341
|
Cost of goods
sold
|
|
1,023,205
|
927,260
|
1,883,334
|
1,822,668
|
Gross
profit
|
|
$
|
135,656
|
$
|
167,314
|
$
|
328,610
|
$
|
294,673
|
Selling, general and
administrative expenses
|
|
110,924
|
117,833
|
226,804
|
236,734
|
Earnings before the
following:
|
|
$
|
24,732
|
$
|
49,481
|
$
|
101,806
|
$
|
57,939
|
Restructuring and
other related costs
|
|
1,190
|
1,507
|
2,858
|
1,338
|
Other
expense
|
|
3,617
|
2,719
|
8,159
|
6,488
|
Earnings before
interest and income taxes
|
|
$
|
19,925
|
$
|
45,255
|
$
|
90,789
|
$
|
50,113
|
Interest expense and
other financing costs
|
|
5,711
|
8,068
|
10,679
|
15,960
|
Earnings before
income taxes
|
|
$
|
14,214
|
$
|
37,187
|
$
|
80,110
|
$
|
34,153
|
Income tax
expense
|
|
5,440
|
11,528
|
23,644
|
12,206
|
Net
earnings
|
|
$
|
8,774
|
$
|
25,659
|
$
|
56,466
|
$
|
21,947
|
|
|
|
|
|
|
Earnings per share
attributable to common
shareholders:
|
|
|
|
|
|
Basic earnings per
share
|
|
$
|
0.07
|
$
|
0.21
|
$
|
0.46
|
$
|
0.18
|
Diluted earnings per
share
|
|
$
|
0.07
|
$
|
0.21
|
$
|
0.45
|
$
|
0.18
|
Weighted average
number of shares (millions):
|
|
|
|
|
|
Basic
|
|
123.4
|
123.1
|
123.3
|
123.0
|
Diluted
|
|
125.5
|
124.2
|
125.5
|
124.1
|
Consolidated Interim Statements of Other Comprehensive Income
(Loss)
(In thousands of
Canadian dollars)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
(Unaudited)
|
2021
|
2020
|
2021
|
2020
|
|
|
|
|
|
|
Net
earnings
|
|
$
|
8,774
|
$
|
25,659
|
$
|
56,466
|
$
|
21,947
|
Other comprehensive
income (loss)
|
|
|
|
|
|
Actuarial gains
(losses) that will not be reclassified to profit or loss (Net of
tax of $0.1 million and $24.9
million; 2020: $12.7 million and 15.2 million)
|
|
$
|
233
|
$
|
(37,066)
|
$
|
73,161
|
$
|
(44,286)
|
Items that are or may
be reclassified subsequently to profit or loss:
|
|
|
|
|
|
Change in accumulated
foreign currency translation adjustment (Net of tax of $0.0 million
and $0.0 million; 2020: $0.0
million and $0.0 million)
|
|
$
|
(4,685)
|
$
|
(8,063)
|
$
|
(10,150)
|
$
|
13,537
|
Change in foreign
exchange on long-term debt designated as a net investment hedge
(Net of tax of $0.8 million and
$1.5 million; 2020: $1.4 million and $2.1 million)
|
|
3,464
|
7,819
|
7,282
|
(11,300)
|
Change in cash flow
hedges (Net of tax of $0.5 million and $2.4 million; 2020: $0.1
million and $6.6 million)
|
|
1,201
|
(388)
|
6,792
|
(18,819)
|
Total items that are
or may be reclassified subsequently
to
profit or loss
|
|
$
|
(20)
|
$
|
(632)
|
$
|
3,924
|
$
|
(16,582)
|
Total other
comprehensive income (loss)
|
|
$
|
213
|
$
|
(37,698)
|
$
|
77,085
|
$
|
(60,868)
|
Comprehensive income
(loss)
|
|
$
|
8,987
|
$
|
(12,039)
|
$
|
133,551
|
$
|
(38,921)
|
Consolidated Interim Statements of Changes in Total
Equity
|
|
|
|
Accumulated
other
comprehensive income
(loss)(i)
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
Share capital
|
Retained earnings
|
Contributed surplus
|
Foreign
currency
translation
adjustment
|
Unrealized
gains and
losses on
cash flow
hedges
|
Treasury
stock
|
Total equity
|
Balance at
December 31, 2020
|
$
|
838,969
|
1,124,973
|
5,866
|
3,002
|
(16,416)
|
(23,930)
|
$
|
1,932,464
|
Net
earnings
|
—
|
56,466
|
—
|
—
|
—
|
—
|
56,466
|
Other
comprehensive income (loss)(ii)
|
—
|
73,161
|
—
|
(2,868)
|
6,792
|
—
|
77,085
|
Dividends declared
($0.36 per share)
|
—
|
(44,375)
|
—
|
—
|
—
|
—
|
(44,375)
|
Share-based
compensation expense
|
—
|
—
|
9,229
|
—
|
—
|
—
|
9,229
|
Deferred taxes on
share-based compensation
|
—
|
—
|
(450)
|
—
|
—
|
—
|
(450)
|
Exercise of stock
options
|
1,929
|
—
|
—
|
—
|
—
|
—
|
1,929
|
Settlement of
share-based compensation
|
—
|
—
|
(9,679)
|
—
|
—
|
5,192
|
(4,487)
|
Change in obligation
for repurchase of shares
|
(668)
|
—
|
(1,780)
|
—
|
—
|
—
|
(2,448)
|
Balance at June
30, 2021
|
$
|
840,230
|
1,210,225
|
3,186
|
134
|
(9,624)
|
(18,738)
|
$
|
2,025,413
|
|
|
|
|
|
|
Accumulated other
comprehensive income
(loss)(i)
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment
|
Unrealized
gains and
losses on
cash flow
hedges
|
Treasury
stock
|
Total
equity
|
Balance at December
31, 2019
|
$
|
840,005
|
1,137,450
|
—
|
4,274
|
(1,481)
|
(30,378)
|
$
|
1,949,870
|
Net
earnings
|
—
|
21,947
|
—
|
—
|
—
|
—
|
21,947
|
Other
comprehensive income (loss)(ii)
|
—
|
(44,286)
|
—
|
2,237
|
(18,819)
|
—
|
(60,868)
|
Dividends declared
($0.32 per share)
|
—
|
(39,306)
|
—
|
—
|
—
|
—
|
(39,306)
|
Share-based
compensation expense
|
—
|
—
|
7,841
|
—
|
—
|
—
|
7,841
|
Deferred taxes on
share-based compensation
|
—
|
—
|
500
|
—
|
—
|
—
|
500
|
Exercise of stock
options
|
773
|
—
|
—
|
—
|
—
|
—
|
773
|
Settlement of
share-based compensation
|
—
|
—
|
(9,738)
|
—
|
—
|
6,448
|
(3,290)
|
Change in obligation
for repurchase of shares
|
3,922
|
—
|
4,637
|
—
|
—
|
—
|
8,559
|
Balance at June 30,
2020
|
$
|
844,700
|
1,075,805
|
3,240
|
6,511
|
(20,300)
|
(23,930)
|
$
|
1,886,026
|
|
|
(i)
|
Items that are or
may be subsequently reclassified to profit or
loss.
|
(ii)
|
Included in other
comprehensive income (loss) is the change in actuarial gains and
losses that will not be reclassified to profit or loss and has been
reclassified to retained earnings.
|
Consolidated Interim Statements of Cash Flows
(In thousands of
Canadian dollars)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
(Unaudited)
|
2021
|
2020(i)
|
2021
|
2020(i)
|
CASH PROVIDED BY
(USED IN):
|
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
|
|
|
|
Net
earnings
|
|
$
|
8,774
|
$
|
25,659
|
$
|
56,466
|
$
|
21,947
|
Add (deduct) items not
affecting cash:
|
|
|
|
|
|
Change in fair value
of biological assets
|
|
51,884
|
26,676
|
13,409
|
41,335
|
Depreciation and
amortization
|
|
50,199
|
48,599
|
100,401
|
96,623
|
Share-based
compensation
|
|
4,527
|
3,975
|
9,229
|
7,841
|
Deferred income
taxes
|
|
(16,054)
|
620
|
(9,870)
|
(6,897)
|
Income tax
current
|
|
21,494
|
10,908
|
33,514
|
19,103
|
Interest expense and
other financing costs
|
|
5,711
|
8,068
|
10,679
|
15,960
|
Loss on sale of
long-term assets
|
|
406
|
230
|
693
|
566
|
Asset
impairment
|
|
436
|
1,572
|
436
|
1,572
|
Change in fair value
of non-designated derivatives
|
|
(18,044)
|
(10,074)
|
(8,417)
|
12,666
|
Change in net pension
obligation
|
|
(3,409)
|
2,175
|
(26)
|
4,419
|
Net income taxes
paid
|
|
(15,426)
|
—
|
(46,703)
|
(8,344)
|
Interest
paid
|
|
(5,965)
|
(7,016)
|
(11,393)
|
(14,572)
|
Change in provision
for restructuring and other related costs
|
|
(109)
|
(168)
|
(68)
|
(2,765)
|
Change in derivatives
margin
|
|
35,266
|
12,163
|
(396)
|
(11,794)
|
Other
|
|
(4,964)
|
368
|
(1,358)
|
1,518
|
Change in non-cash
operating working capital
|
|
(84,755)
|
23,384
|
(146,859)
|
(77,836)
|
Cash provided by
(used in) operating activities
|
|
$
|
29,971
|
$
|
147,139
|
$
|
(263)
|
$
|
101,342
|
Investing
activities
|
|
|
|
|
|
|
|
|
|
Additions to long-term
assets
|
|
$
|
(161,273)
|
$
|
(91,626)
|
$
|
(322,240)
|
$
|
(177,918)
|
Interest paid and
capitalized
|
|
(4,638)
|
(1,816)
|
(8,609)
|
(3,011)
|
Acquisition of
business
|
|
(40,151)
|
—
|
(40,151)
|
—
|
Proceeds from sale of
long-term assets
|
|
215
|
8
|
768
|
8
|
Purchase of
investments
|
|
—
|
(101)
|
—
|
(13,953)
|
Cash used in
investing activities
|
|
$
|
(205,847)
|
$
|
(93,535)
|
$
|
(370,232)
|
$
|
(194,874)
|
Financing
activities
|
|
|
|
|
|
|
|
|
Dividends
paid
|
|
$
|
(22,267)
|
$
|
(19,740)
|
$
|
(44,375)
|
$
|
(39,306)
|
Net increase in
long-term debt
|
|
164,861
|
(139)
|
389,722
|
164,722
|
Payment of lease
obligation
|
|
(9,290)
|
(9,005)
|
(18,681)
|
(18,114)
|
Exercise of stock
options
|
|
523
|
773
|
1,929
|
773
|
Payment of financing
fees
|
|
(50)
|
(562)
|
(50)
|
(599)
|
Cash provided by
(used in) financing activities
|
|
$
|
133,777
|
$
|
(28,673)
|
$
|
328,545
|
$
|
107,476
|
(Decrease)
increase in cash and cash equivalents
|
|
$
|
(42,099)
|
$
|
24,931
|
$
|
(41,950)
|
$
|
13,944
|
Cash and cash
equivalents, beginning of period
|
|
100,977
|
86,298
|
100,828
|
97,285
|
Cash and cash
equivalents, end of period
|
|
$
|
58,878
|
$
|
111,229
|
$
|
58,878
|
$
|
111,229
|
|
|
(i)
|
Certain
comparative figures have been restated to conform with current year
presentation.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/maple-leaf-foods-reports-second-quarter-2021-financial-results-301349119.html
SOURCE Maple Leaf Foods Inc.